We are live on ! Find out more
AG

Artal Group Portfolio holdings

AUM $1.01B
1-Year Est. Return 29.84%
This Fund
S&P 500
This Quarter Est. Return
+8.65%
1 Year Est. Return
+29.84%
3 Year Est. Return
+144%
5 Year Est. Return
+76.57%
10 Year Est. Return
+1,417.6%
AUM
$6.63B
AUM Growth
+$825M
Cap. Flow
+$471M
Cap. Flow %
7.11%
Top 10 Hldgs %
82.61%
Holding
140
New
29
Increased
38
Reduced
20
Closed
21

Top Buys

Rank Stock Value
1
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$25.1M
2
INCY icon
Incyte
INCY
+$10.5M
3
DNLI icon
Denali Therapeutics
DNLI
+$8.99M
4
LXRX icon
Lexicon Pharmaceuticals
LXRX
+$7.86M
5
ALBO
Albireo Pharma Inc
ALBO
+$7.61M

Top Sells

Rank Stock Value
1
NKTR icon
Nektar Therapeutics
NKTR
+$33.5M
2
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$17.4M
3
RXDX
Ignyta, Inc.
RXDX
+$11.1M
4
NBIX icon
Neurocrine Biosciences
NBIX
+$10.2M
5
SRPT icon
Sarepta Therapeutics
SRPT
+$9.07M

Sector Composition

Rank Sector Weight
1 Consumer Staples 43.26%
2 Consumer Discretionary 19.67%
3 Healthcare 17.59%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RARE icon
126
Ultragenyx Pharmaceutical
RARE
$2.48B
– –
-50,000
Closed -$2.66M
SRPT icon
127
Sarepta Therapeutics
SRPT
$1.66B
– –
-200,000
Closed -$9.07M
TER icon
128
CALL
Teradyne
TER
$53.3B
– –
-350,000
Closed -$13.1M
LUMO
129
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
– –
-16,667
Closed -$1.38M
ARAV
130
DELISTED
Aravive, Inc. Common Stock
ARAV
– –
-66,667
Closed -$980K
SGEN
131
CALL
DELISTED
Seagen Inc. Common Stock
SGEN
– –
-100,000
Closed -$5.44M
BLCM
132
CALL
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
– –
-20,000
Closed -$2.31M
SIOX
133
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
– –
-62,500
Closed -$3.44M
GBT
134
CALL
DELISTED
Global Blood Therapeutics, Inc.
GBT
– –
-250,000
Closed -$7.76M
FPRX
135
DELISTED
Five Prime Therapeutics, Inc.
FPRX
– –
-50,000
Closed -$2.05M
WUBA
136
CALL
DELISTED
58.com Inc
WUBA
– –
-200,000
Closed -$12.6M
HZNP
137
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
– –
-500,000
Closed -$7.02M
RXDX
138
DELISTED
Ignyta, Inc.
RXDX
– –
-900,000
Closed -$11.1M
DMTX
139
DELISTED
Dimension Therapeutics, Inc
DMTX
– –
-234,493
Closed -$1.41M
BHVN
140
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
– –
-50,000
Closed -$1.87M
2 3 4 5
6

Similar funds

BCM
Bronte Capital Management Bondi Junction, Australia $1.01B AUM 47.99% 1-Year Est. Return
GA
GRS Advisors Chicago, Illinois $1.01B AUM 13.12% 1-Year Est. Return
EPAM
Euro Pacific Asset Management Dorado, Puerto Rico $1.01B AUM 79.26% 1-Year Est. Return
WA
Wealth Alliance Mellville, New York $1.01B AUM 19.71% 1-Year Est. Return
CT
Coastline Trust Providence, Rhode Island $1.01B AUM 22.57% 1-Year Est. Return
AH
Allen Holding New York $1.01B AUM 27.61% 1-Year Est. Return
PIM
Provident Investment Management Novi, Michigan $1.01B AUM 9.4% 1-Year Est. Return
MAM
Melqart Asset Management London, United Kingdom $1.01B AUM 84.85% 1-Year Est. Return

Artal Group's Q4 2017 Portfolio in Review

As of Q4 2017, Artal Group held 140 positions worth $6.63B, up 14% from $5.81B the previous quarter. Its ten largest holdings account for 83% of the portfolio.

Artal Group deployed $471M of net new capital in Q4 2017, opening 29 new positions and adding to 38 existing holdings. Its largest new stake was Denali Therapeutics: 500,000 shares worth $7.82M.

By sector, the portfolio is most concentrated in Consumer Staples at 43% of assets, up from 43% a quarter earlier, followed by Consumer Discretionary and Healthcare.

On the sell side, the largest reduction was Nektar Therapeutics, an estimated $33.5M trimmed.

  • Artal Group's largest Q4 2017 buy was Denali Therapeutics: 500,000 shares worth $7.82M.
  • Artal Group added most to Alnylam Pharmaceuticals in Q4 2017, an estimated $25.1M increase.
  • Artal Group's biggest Q4 2017 reduction was Nektar Therapeutics, cutting an estimated $33.5M.
  • Artal Group fully exited BioMarin Pharmaceuticals in Q4 2017, selling an estimated $17.4M.
  • Artal Group's ten largest holdings make up 83% of its $6.63B portfolio in Q4 2017.
  • Artal Group opened 29 new positions and closed 21 in Q4 2017.
  • Artal Group's portfolio value rose 14% quarter-over-quarter to $6.63B.

Based on Artal Group's 13F filing for Q4 2017, filed 9 Feb 2018.